Effects of intermediate-conductance Ca2+-activated K+ channel modulators on human prostate cancer cell proliferation

Eur J Pharmacol. 2003 Jun 27;471(3):157-64. doi: 10.1016/s0014-2999(03)01825-9.

Abstract

The effects of 1-ethyl-2-benzimidazolinone (1-EBIO) and riluzole on human prostate cancer cells, LNCaP and PC-3, were evaluated using rubidium (86Rb(+)) efflux and proliferation assays. 1-EBIO and riluzole evoked concentration-dependent increases in 86Rb(+) efflux from LNCaP and PC-3 cells that were sensitive to inhibition by intermediate-conductance Ca(2+)-activated K(+) channel (IK(Ca)) blockers clotrimazole and charybdotoxin. Blockers of large-conductance Ca(2+)-activated K(+) (BK(Ca)) channel, iberiotoxin, or small-conductance Ca(2+)-activated K(+) (SK(Ca)) channel, apamin or scyllatoxin, had no effect. Concurrently, both 1-EBIO and riluzole evoked concentration-dependent increases in proliferation from human prostate cancer cell lines (LNCaP and PC-3 cells). Clotrimazole and charybdotoxin, but not iberiotoxin, apamin or scyllatoxin, inhibited 1-EBIO- and riluzole-evoked increases in proliferation from LNCaP and PC-3 cells. N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorophenyl)urea (NS-1608) and 2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile (NS-8), BK(Ca) channel openers had no effect on LNCaP and PC-3 proliferation. These results demonstrate that IK(Ca) channels play an important role in the regulation of human prostate cancer cell proliferation.

MeSH terms

  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use
  • Calcium Channel Agonists / pharmacology*
  • Calcium Channel Agonists / therapeutic use
  • Calcium Channel Blockers / pharmacology*
  • Calcium Channel Blockers / therapeutic use
  • Cell Division / drug effects
  • Cell Division / physiology
  • Cell Line, Tumor / cytology
  • Cell Line, Tumor / drug effects
  • Cell Line, Tumor / physiology
  • Dose-Response Relationship, Drug
  • Humans
  • Male
  • Potassium Channels, Calcium-Activated / agonists*
  • Potassium Channels, Calcium-Activated / antagonists & inhibitors*
  • Potassium Channels, Calcium-Activated / physiology
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Riluzole / pharmacology
  • Riluzole / therapeutic use

Substances

  • Benzimidazoles
  • Calcium Channel Agonists
  • Calcium Channel Blockers
  • Potassium Channels, Calcium-Activated
  • Riluzole
  • 1-ethyl-2-benzimidazolinone